WuXi PharmaTech (Cayman) Inc. is a pharmaceutical, biotechnology and medical device research and development (R&D) services company, with operations in China and the United States. The Company provides a portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process to its customers. It conducts its operations in two segments: Laboratory services and Manufacturing services. The Company offers Laboratory services for pharmaceutical, biotechnology and medical device companies. It offers Manufacturing services, which include the development of manufacturing processes and the production of advanced intermediates and active pharmaceutical ingredients (APIs) for use by pharmaceutical companies in preclinical and clinical trials of small-molecule products and in commercial products, as well as the production of biologic products.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: NYSE:WX
- CUSIP: N/A
- Web: N/A
- 50 Day Moving Avg: $45.00
- 200 Day Moving Avg: $43.00
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 25.93
- P/E Growth: 0
- Net Margins: 7.52%
- Return on Equity: 6.93%
- Return on Assets: 4.67%
Frequently Asked Questions for WuXi PharmaTech (Cayman) (NYSE:WX)
What is WuXi PharmaTech (Cayman)'s stock symbol?
WuXi PharmaTech (Cayman) trades on the New York Stock Exchange (NYSE) under the ticker symbol "WX."
How were WuXi PharmaTech (Cayman)'s earnings last quarter?
WuXi PharmaTech (Cayman) Inc. (NYSE:WX) posted its quarterly earnings results on Tuesday, November, 3rd. The company reported $0.31 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.31. The business earned $213.60 million during the quarter, compared to analyst estimates of $205.24 million. WuXi PharmaTech (Cayman) had a return on equity of 6.93% and a net margin of 7.52%. The business's revenue was up 23.0% compared to the same quarter last year. During the same period in the prior year, the business earned $0.54 earnings per share. View WuXi PharmaTech (Cayman)'s Earnings History.
Who are some of WuXi PharmaTech (Cayman)'s key competitors?
Some companies that are related to WuXi PharmaTech (Cayman) include Ionis Pharmaceuticals (IONS), Icon Plc (ICLR), INC Research Holdings (INCR), Exact Sciences Corporation (EXAS), Galapagos NV (GLPG), Charles River Laboratories International (CRL), United Therapeutics Corporation (UTHR), PRA Health Sciences (PRAH), ACADIA Pharmaceuticals (ACAD), Bio-Techne Corp (TECH), PAREXEL International Corporation (PRXL), FibroGen (FGEN), Puma Biotechnology (PBYI), Nektar Therapeutics (NKTR), Portola Pharmaceuticals (PTLA), Ligand Pharmaceuticals Incorporated (LGND), Blueprint Medicines Corporation (BPMC) and Sage Therapeutics (SAGE).
How do I buy WuXi PharmaTech (Cayman) stock?
Shares of WuXi PharmaTech (Cayman) can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is WuXi PharmaTech (Cayman)'s stock price today?
MarketBeat Community Rating for WuXi PharmaTech (Cayman) (NYSE WX)MarketBeat's community ratings are surveys of what our community members think about WuXi PharmaTech (Cayman) and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of WuXi PharmaTech (Cayman) stock can currently be purchased for approximately $45.90.
Consensus Ratings for WuXi PharmaTech (Cayman) (NYSE:WX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for WuXi PharmaTech (Cayman) (NYSE:WX)
(Data available from 9/24/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/5/2015||Morgan Stanley||Downgrade||Overweight -> Equal Weight||N/A|
Earnings History for WuXi PharmaTech (Cayman) (NYSE:WX)Earnings History by Quarter for WuXi PharmaTech (Cayman) (NYSE WX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/3/2015||Q3||$0.31||$0.31||$205.24 million||$213.60 million||View||N/A|
|8/13/2015||Q215||$0.39||$0.38||$195.26 million||$194.14 million||View||Listen|
|5/13/2015||Q1||$0.32||$0.36||$174.29 million||$180.00 million||View||Listen|
|3/5/2015||Q414||$0.53||$0.55||$189.54 million||$190.60 million||View||Listen|
|11/12/2014||Q314||$0.48||$0.54||$172.60 million||$173.60 million||View||Listen|
|8/13/2014||Q214||$0.47||$0.49||$162.11 million||$163.40 million||View||Listen|
|5/14/2014||Q114||$0.39||$0.30||$145.00 million||$146.70 million||View||Listen|
|3/5/2014||Q413||$0.43||$0.53||$155.76 million||$157.10 million||View||N/A|
|11/13/2013||Q313||$0.39||$0.47||$145.29 million||$146.70 million||View||Listen|
|8/12/2013||Q2 2013||$0.39||$0.46||$141.10 million||$142.33 million||View||N/A|
|5/13/2013||Q1 2013||$0.32||$0.35||$130.02 million||$131.90 million||View||Listen|
|3/7/2013||Q4 2012||$0.30||$0.38||$123.71 million||$125.70 million||View||Listen|
|11/12/2012||Q312||$0.30||$0.36||$123.17 million||$125.84 million||View||N/A|
Earnings Estimates for WuXi PharmaTech (Cayman) (NYSE:WX)
Current Year EPS Consensus Estimate: $1.51 EPS
Next Year EPS Consensus Estimate: $1.77 EPS
Dividend History for WuXi PharmaTech (Cayman) (NYSE:WX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for WuXi PharmaTech (Cayman) (NYSE:WX)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for WuXi PharmaTech (Cayman) (NYSE:WX)
Latest Headlines for WuXi PharmaTech (Cayman) (NYSE:WX)
WuXi PharmaTech (Cayman) (WX) Chart for Sunday, September, 24, 2017